Phototherapy as a First Line Treatment for Mycosis Fungoides: A 10-year Retrospective Study by Azevedo, Alexandra et al.
215
Artigo Original
Fototerapia como Primeira Linha Terapêutica para a 
Micose Fungóide: Um Estudo Retrospetivo de 10 Anos  
Alexandra Azevedo1, Iolanda Fernandes1,3,4, Renata Cabral2,3,4, Margarida Lima2,3,4,5, Isabel Amorim1, Manuela Selores1,5
1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
2Department of Hematology, Centro Hospitalar Universitário do Porto, Porto, Portugal
3Multidisciplinary Outpatient Clinic for Cutaneous Lymphomas and Mastocytosis, Centro Hospitalar do Porto, Porto, Portugal.
4Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
5Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
RESUMO – Introdução: A fototerapia, em particular a fotoquimioterapia com psoralenos associados a radiações ultravio-
leta do tipo A (PUVA) e a fototerapia com radiações ultravioleta do tipo B de banda estreita (nbUVB), é um dos pilares do 
tratamento da micose fungóide (MF). Métodos: Foram analisados os resultados de doentes com MF que fizeram tratamento 
de primeira linha com PUVA ou nbUVB na Unidade de Fotodermatologia do Serviço de Dermatologia do Centro Hospitalar 
Universitário do Porto, de 2007 a 2017. O resultado primário foi a resposta ao tratamento. O resultado secundário foi a 
sobrevida livre de recidiva. Resultados: De um total de 34 doentes com MF, nove (26,5%) foram diagnosticados no estadio 
IA e 25 (73,5%) no estadio IB. Destes doentes, 30 (88,2%) foram tratados com PUVA e quatro (11,8%) com nbUVB. Global-
mente, 24 (80%) doentes tratados com PUVA e dois (50%) doentes tratados com nbUVB tiveram respostas completas. Foi 
observada recidiva em 17 (70,8%) doentes tratados com PUVA e em dois (100%) doentes tratados com nbUVB. A mediana 
da sobrevida livre de recidiva foi de 12 meses para o grupo PUVA e 6 meses para o grupo nbUVB. Conclusão: A fotoqui-
mioterapia com PUVA é uma terapêutica eficaz na MF em estadios precoces. O UVB de banda estreita pode ser uma alter-
nativa terapêutica válida para estes doentes. Todavia, a amostra reduzida do grupo nbUVB neste estudo limita as conclusões 
sobre a sua eficácia. 
PALAVRAS-CHAVE – Fármacos Fotossensibilizantes; Fototerapia; Micose Fungóide/tratamento; Terapia PUVA.
Phototherapy as a First Line Treatment for Mycosis 
Fungoides: A 10-year Retrospective Study 
ABSTRACT – Introduction: Phototherapy, particularly psoralen plus ultraviolet A (PUVA) and narrowband ultraviolet B (nbUVB), 
is a mainstay in the treatment of Mycosis Fungoides (MF). Methods: We analyzed outcomes of MF patients treated for the 
first time with either PUVA or nbUVB at the Photodermatology Unit, in the Department of Dermatology of Centro Hospitalar 
Universitário do Porto, from 2007 to 2017. The primary outcome was response to treatment. The secondary outcome was disease 
relapse free survival. Results: From a total number of 34 patients with MF identified, nine (26.5%) patients were diagnosed at 
stage IA and 25 (73.5%) patients were diagnosed at stage IB. Of these patients, 30 (88.2%) were treated with PUVA and four 
(11.8%) with nbUVB. Overall, 24 (80%) patients treated with PUVA and two (50%) patients treated with nbUVB had complete 
responses (CR). Relapse was observed in 17 (70.8%) PUVA treated patients and two (100%) nbUVB treated patients. Median 
disease relapse free survival was 12 months for PUVA and 6 months for nbUVB. Conclusion: PUVA is an effective therapy in early 
MF. Narrowband UVB could be a valid therapeutic alternative for these patients. However, the small size of nbUVB group in our 
study limits the conclusions about its efficacy. 
KEYWORDS – Mycosis Fungoides/therapy; PUVA Therapy; Photosensitizing Agents; Phototherapy.
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INTRODUCTION
Primary cutaneous lymphomas are defined as non-Hod-
gkin lymphomas present in the skin without evidence of ex-
tracutaneous disease at the time of diagnosis.1 In the western 
world, cutaneous T cell lymphomas (CTCL) account to about 
75% to 80% of all primary cutaneous lymphomas. Mycosis 
fungoides (MF) is the most common type of CTCL, with 75% 
of affected patients being at early stage during initial diag-
nosis.2,3
Skin-directed therapies, including phototherapy, are a 
mainstay treatment for most patients with early stage MF.4 
Both narrow-band ultraviolet B light (nbUVB) phototherapy 
and psoralen plus ultraviolet A light (PUVA) photochemothe-
rapy, have recognized efficacy in MF and are widely used 
treatments for early stages.5 
Despite the large use of phototherapy on early stage MF, 
exact mechanisms of action are currently unknown. The pri-
mary direct effects of UVB are on cell population localized 
in the epidermis and the upper dermis. The hypothesized 
mechanisms of action of nbUVB on MF include apoptosis of 
keratinocytes and infiltrating lymphocytes, inhibition of kera-
tinocyte growth rate and lowered production of pro-inflam-
matory cytokines in lesion’s microenvironment and increased 
production of anti-inflammatory cytokine.6 The theoretical 
advantages of PUVA over nbUVB are in terms of reduced 
erythemogenic activity and better penetration towards dee-
per dermal layers, up to hypodermis and deepest adnexal 
structures, where can affect lymphocytes as well as other resi-
dent skin cells, such as fibroblasts, dendritic cells, mast cells, 
endothelial cells or macrophages.5,6 
We conducted a retrospective study to evaluate the effi-
cacy of phototherapy, particularly PUVA and nbUVB, in early 
stage MF, in a tertiary hospital of Porto, Portugal. 
METHODS
Study design and population
We retrospectively reviewed all patients treated with pho-
totherapy for MF at the Photodermatology Unit, in the De-
partment of Dermatology of Centro Hospitalar Universitário 
do Porto, in a 10-year time period (from 2007 to 2017). 
The cohort included all patients with early-stage MF who had 
been treated for the first time with either PUVA or nbUVB. 
All patients had stage IA or IB disease. The stage of the 
disease was determined according to the TNMB classification 
by the International Society for Cutaneous Lymphoma and 
Cutaneous Lymphoma Task Force of the European Organi-
zation for the Research and Treatment of Cancer (EORTC).3
Patients with more advanced stages of MF, other types 
of cutaneous T-cell lymphoma, patients who received any 
concurrent treatments (e.g. interferon, acitretin, etc.) or with 
missing data pertaining to the primary study outcome were 
excluded in the study population. 
Patient’s medical records were reviewed, and demogra-
phic (gender and age) and clinical data (phototype, disea-
se duration, response, side effects and treatment protocols) 
were collected.
Phototherapy treatment protocol
Both PUVA and nbUVB are used to treat MF. Physicians 
determine treatment type based on patient’s comorbidities, 
disease stage and type of skin lesions (patches versus pla-
ques). Phototherapy was the only treatment for all cases 
included in this analysis, and no other systemic treatment 
was applied during the observation period.
Phototherapy sessions were carried out two times per 
week. Concerning PUVA treatment, 8-methoxypsoralen 0.6 
mg/kg was administered two hours prior to therapy session. 
The initial UVA doses were calculated according to each 
patient’s skin type (I, 0.5 J/cm2; II, 1 J/cm2; III, 1.5 J/cm2; 
IV, 2 J/cm2). Fixed dosage increments during therapy were 
also consistent with skin phototype ((40% of previous dose 
or 20% if patients developed erythema during treatment). 
Concerning nbUVB, the starting dose (I and II, 0.1 J/cm2; 
III e IV, 0.2 J/cm2). and dosage increments (20% of pre-
vious dose or 10% if patients developed erythema during 
treatment) were adjusted to the skin type. PUVA and nbUVB 
treatment were continued until complete skin clearance or 
no further clinical improvement was noted. Patients were 
not submitted to a maintenance regimen. 
Outcomes
The primary outcome was response to treatment achie-
ved by patients who received PUVA and nbUVB treatment. 
The secondary outcome was disease relapse free survival in 
PUVA treated and nbUVB treated patients.
Responses were defined according to the consensus 
statement of the International Society for Cutaneous Lym-
phomas (ISCL) as follows: complete response (CR), com-
plete clearance of all skin lesions; partial response (PR) with 
>50% remission of skin lesions; no response (NR), any cli-
nical result less than a PR;  disease progression, ≥ 25% 
increase in skin disease from baseline or development of 
new tumors (T3) in patients with T1, T2 or T4 with only skin 
involvement; relapse, any clinically significant disease ree-
mergence requiring further treatment.7
Disease relapse free survival was defined as time from 
treatment completion to clinically significant disease ree-
mergence requiring further treatment. 
Statistical analysis
The small sample size did not allow a comparative 
analysis between the PUVA-treated group and the nbUVB-
-treated group nor the identification of variables predicting 
relapse. Kaplan–Meier analysis was performed to plot re-
lapse-free rates after phototherapy modalities.
All analyses were performed using the IBM SPSS Statis-
tics 24.0 (SPSS, Chicago, IL, USA).
RESULTS
Patient Characteristics
Thirty-four patients with early stage MF, fourteen fema-
les (41.2%) and 20 males (58.8%), were included.  Thirty 
cases (88.2%) were treated with PUVA, while four (11.8%) 
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received nbUVB. The median age at diagnosis was 59 years 
in the PUVA group and 57 years in the nbUVB group. All 
patients had stage IA or IB disease. In PUVA group, eight 
patients (27%) had stage IA MF and 22 patients (73%) had 
stage IB MF. In the nbUVB group, one patient (25%) had 
stage IA MF and three patients (75%) had stage IB MF. Table 
1 summarizes patients’ clinical data.
Treatment outcome
Overall, 24 patients (80%) of the PUVA group and two 
patients (50%) of the nbUVB group achieved CR (Fig. 1). In 
PUVA group, four patients (13.4%) discontinued treatment, 
two of them (6.7%) due to adverse reactions and another two 
patients (6.7%) because of several missed sessions. In nbUVB 
group, one patient (25%) suspended phototherapy due to 
an adverse event and another patient (25%) due to several 
missed sessions.
Median number of treatment sessions to achieve comple-
te response was of 30 for PUVA and of 23 for nbUVB. Me-
dian irradiation dose was 270.4 J/cm2 for PUVA and 16.3 
J/cm2 for nbUVB.
Disease relapse was observed in 17 out of 24 patients 
with CR (70.8%) treated with PUVA group (follow-up between 
3 and 108 months) and in two out of two patients with CR 
(100%) treated with nbUVB group. The median disease-free 
survival (DFS) was 12 months (range 4-35) in PUVA group 
and 6 months (range 3-8) in nbUVB group (Fig. 2). Relapse-
-free rate at 1 year was 53% in PUVA group and 100% in 
nbUVB group. 
Ten patients had at least one more round of PUVA the-
rapy after disease relapse. Two of those had to have PUVA 
treatment stopped early for personal reasons. The remai-
ning eight patients responded completely to the second 
round of PUVA therapy. Disease relapse was observed in 
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Table 1 - Patient clinical characteristics. 
CLINICAL CHARACTERISTICS PHOTOTHERAPY GROUP
nbUVB (n=4) PUVA (n=30)
Gender, n (%)
Females
Males
1 (25)
3 (75)
13 (43)
17 (57)
Age at diagnosis (years)* 57 (27-63) 59 (29-79)
Phototype, n (%)
I
II
III
0 (0)
0 (0)
4 (100)
3 (10)
12 (40)
15 (50)
Stage, n (%)
IA
IB
1 (25)
3 (75)
8 (27)
22 (73)
N= number of patients; nbUVB= narrowband ultraviolet-B light photo-
therapy; PUVA= psoralen plus ultraviolet A light phototherapy. 
* Results are presented as median and (minimum-maximum) values.
Figure 1 - Response to treatment achieved by patients who received PUVA and nbUVB treatment.  
Figure 2 - Kaplan–Meier analysis of disease relapse free survival after 
first PUVA or nbUVB treatments. 
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seven out of eight patients who had a CR after the second 
round of PUVA. The mean time to relapse was 11 months 
(range 3-24) (Fig. 3).
Safety
Regarding PUVA-induced toxicities, two patients repor-
ted erythema and one patient report pruritus. Among these 
patients, two discontinued treatment due to side effects’ se-
verity. In nbUVB group, one patient stopped therapy due to 
polymorphous light eruption.
DISCUSSION
The first publication on the use of PUVA phototherapy 
for the treatment of MF was in 1976,8 and since then, more 
than 30 studies of treatment with PUVA in patients with MF 
have been published in English. It is difficult to compare re-
sults of the reports because there were differences in treat-
ment protocols for the clearance and maintenance phases, 
heterogeneity of the quality of studies, sample size or pa-
tient selection and differences in outcome measures, relap-
se definition or definition of time of relapse.5 
Our experience with this series of 30 patients confirms 
the efficacy and safety of treatment with PUVA in patients 
with stage IA and IB MF. Overall, 80% of patients treated 
with PUVA achieved CR and 3.3% of patients achieved PR. 
These findings are in accordance with other studies, that 
reported PUVA-induced CR rates between 62%-92%.9-14 In a 
Portuguese study published by Ponte et al, PUVA treatment 
led to CR in 62.1% of the patients.12 The relapse rate ran-
ged from 36% to 92% in recent studies, with a mean relap-
se-free interval ranging from 12 to 57 months. Our results 
showed a relapse rate of 71%, with a median relapse-free 
interval of 12 months. These results are in accordance with 
Ponte and colleagues, who reported a relapse rate of 90% 
after PUVA, with a mean relapse-free interval of 12 mon-
ths.12
Narrowband UVB has been used since at least 1999 for 
the treatment of MF.15 Our nbUVB group is smaller (four 
patients) than most of the published groups, with samples 
ranging from 14 to 109 patients.9,12,14,16-24 In our series, 
nbUVB led to CR in 50% of patients, with a median relapse-
-free interval of 6 months. However, the small size of nbUVB 
group limits the interpretation of these results. Other publi-
shed studies, reported CR rates between 54% - 91%, relap-
se rates ranged from 5% to 83%, with a mean relapse-free 
interval ranging from 5 to 26 months.9,12,14,16-24
Data about the efficacy of a second course of photothe-
rapy after MF relapse is limited. Abel et al reported a CR in 
50% of the patients (n=6) after a second clearing phase of 
PUVA therapy. Disease relapse was observed in all patients 
with CR after the second course of PUVA.25 Querfeld et al 
reported that most of patients responded again when PUVA 
treatment was resumed more intensively after disease re-
lapse, and 36% of relapse patients remained disease free at 
last follow-up.26 Wackernagel et al observed a CR in seven 
of 10 (70%) patients who received a second round of PUVA 
therapy after disease relapse. Disease relapse was reported 
in six of seven (86%) patients after the second successful 
course of PUVA; the mean time to relapse was 11 months.11 
In contrast to these three studies, our PUVA treatment proto-
col did not include a maintenance regimen. Still, we found 
similar results, with eight of 10 (80%) patients achieving CR 
after the second round of PUVA therapy. The disease relap-
se rate was 88% after the second course of phototherapy, 
with a mean time to relapse of 11 months.
The present study was limited by the small number of 
patients included and by its observational and retrospective 
design.
Narrowband UVB is a valid therapeutic option in early 
stage MF and several studies demonstrated no difference 
between PUVA and nbUVB in early stage MF in terms of 
responses and time to relapse, but the results from these 
studies are difficult to compare.6 In addition, a recent 
large retrospective study showed that PUVA treatment re-
sults in better response rates and longer relapse-free inter-
vals in both patch and plaque stage, compared to nbUVB 
treatment.14 Still, the small size of nbUVB group limits the 
conclusions about its efficacy and comparison with PUVA 
efficacy. Therefore, there is an unmet need for a prospecti-
ve, randomized, controlled study to compare the efficacy of 
both modalities of phototherapy and to clarify other specific 
issues, namely the impact of the maintenance protocol on 
the outcome and the relapse rates once long-term mainte-
nance is stopped.
In conclusion, although our study was limited by the 
small number of patients included, and by its observatio-
nal and retrospective design, the results obtained are in 
accordance with previous publications about the effica-
cy and safety of PUVA treatment in stage IA and IB MF. 
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Figure 3 - Kaplan–Meier analysis of disease relapse free survival after 
a second round of PUVA after disease relapse.
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